Company Profile
BioMarin Pharmaceutical Stock Price, News & Analysis
- Ticker:
- BMRN
- Exchange:
- NASDAQ
- Sector:
- Gene Therapy
- Location:
- San Rafael, California
Stock performance
61.46 USD (+2.59%)
Close
Last updated: August 6, 2026
10.3B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, BMRN closed up 2.59% at $61.46. No new same-company headline was identified in the current news window.
Company overview
Business overview
BioMarin is a rare-disease biotechnology company with a portfolio built around enzyme therapies, rare disease commercialization, and pipeline expansion. It remains one of the clearest pure-play rare-disease names in public biotech.
Geographic Base and Sector Classification
Headquartered in San Rafael, California and listed on NASDAQ, BioMarin is a U.S.-based rare-disease biotech with global commercial reach. It sits in specialty biotechnology rather than broad pharma.
Business Model Characteristics
The company generates value through orphan-drug commercialization, label expansion, and a pipeline aimed at additional rare conditions. Investors focus on product adoption, revenue growth, and the durability of the rare-disease franchise.
Position Within the Biotechnology Landscape
BioMarin occupies a premium niche within biotech because rare disease can support pricing power and durable commercial growth. It is less binary than early-stage oncology names, but data and regulatory milestones still matter.
Future catalysts
BioMarin’s catalysts are Voxzogo commercial growth, Roctavian uptake, and any enzyme-therapy or gene-therapy update that helps the portfolio. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
Recent news
- 01
BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
Source: BioMarin Pharmaceutical
- 02
BioMarin to Attend Three Upcoming Investor Conferences
Source: BioMarin Pharmaceutical
- 03
BioMarin Announces Third Quarter 2016 Financial Results
Source: BioMarin Pharmaceutical
- 04
BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting
Source: BioMarin Pharmaceutical
- 05
UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A
Source: BioMarin Pharmaceutical
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BioMarin Pharmaceutical (BMRN)?
BioMarin Pharmaceutical (BMRN) most recently closed at 61.46 USD, a +2.59% move versus the previous session.
What is the market cap of BioMarin Pharmaceutical (BMRN)?
BioMarin Pharmaceutical currently has a market capitalization of 10.3B USD on BioPharmSignal.
What does BioMarin Pharmaceutical do?
BioMarin is a rare-disease biotechnology company with a portfolio built around enzyme therapies, rare disease commercialization, and pipeline expansion. It remains one of the clearest pure-play rare-disease names in public biotech.
On which exchange is BMRN stock listed?
BioMarin Pharmaceutical (BMRN) is associated with NASDAQ, San Rafael, California, Gene Therapy.
What is BioMarin?
BioMarin’s catalysts are Voxzogo commercial growth, Roctavian uptake, and any enzyme-therapy or gene-therapy update that helps the portfolio.
Which conditions is BioMarin Pharmaceutical targeting with BioMarin?
BioMarin Pharmaceutical is associated with rare disease based on its company overview and current catalyst commentary.
How does BioMarin Pharmaceutical describe recent progress with BioMarin?
BioMarin’s catalysts are Voxzogo commercial growth, Roctavian uptake, and any enzyme-therapy or gene-therapy update that helps the portfolio.
What is Voxzogo?
BioMarin’s catalysts are Voxzogo commercial growth, Roctavian uptake, and any enzyme-therapy or gene-therapy update that helps the portfolio.